Airway Stent/Lung Stent Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Airway Stent/Lung Stent Market Trends and Insights

Rising Prevalence of Lung and Chronic Respiratory Disorders

Respiratory Research reported 213.39 million COPD cases in 2024, reflecting better diagnostics and longer survival that in turn keep interventional demand high.^{[1]Jinping Zheng, “Global, Regional, and National Burden of Chronic Obstructive Pulmonary Disease,” Respiratory Research, biomedcentral.com} Lung-cancer-related airway obstruction frequently requires palliative stents that restore patency and improve breathing comfort. Smoking, which still drives 34.8% of COPD disability-adjusted life-years, and ambient particulate pollution at 22.2% sustain a large patient pipeline. Aging populations amplify case volumes in developed economies, whereas India alone tallied 37.8 million COPD cases, underscoring opportunity in fast-growing Asia-Pacific markets.^{[2]Prakash P. Doke, “Chronic Respiratory Diseases: A Rapidly Emerging Public Health Concern,” Indian Journal of Public Health, journals.lww.com}

Growing Preference for Minimally Invasive Procedures

High-frequency jet ventilation using silicone catheters achieved 84% procedural success in 2024 with median operating times of 35 minutes and no postoperative complications, strengthening the clinical case for bronchoscopic stenting over open surgery.^{[3]Onur Küçük et al., “Long-Term Results of Intensive Care Patients with Post-Intubation Tracheal Stenosis,” BMC Pulmonary Medicine, bmcpulmmed.biomedcentral.com}Hospitals embrace outpatient protocols to contain costs and accelerate recovery, while cone-beam CT and digital tomosynthesis sharpen placement accuracy. Robotic bronchoscopy systems deliver diagnostic yields of 88-94% for peripheral lesions, further easing physician adoption.

Rapid Material Innovation in 3D-Printed and Drug-Eluting Bioresorbable Stents

The United States FDA cleared Peytant Solutions’ covered stent system under the De Novo pathway in 2024, signaling regulatory openness to next-generation platforms.^{[4]FDA Center for Devices and Radiological Health, “Minima Stent System – P240003,” fda.gov} Michigan Medicine launched a 35-patient infant trial for 3D-printed bioresorbable devices in March 2025, advancing personalized implants that dissolve after airway remodeling. Iron-based bioresorbable scaffolds showed 95.4% absorption within three years while keeping structural integrity during healing in EuroIntervention’s first-in-human study.

Benefits Linked to Pulmonary Stent Usage

Airway stenting delivers immediate dyspnea relief and improves functional scores according to Journal of Bronchology & Interventional Pulmonology findings. In lung-transplant patients, Y-shaped carinal stents cut intervention frequency from 15.6 to 4.8 procedures and extended treatment intervals up to 85.8 days, reducing hospital utilization. The reversibility of silicone devices affords safety margins over permanent surgery and keeps infection rates comparatively low.

Availability of Alternative Interventions

Balloon dilation solves many benign strictures with 88.9% efficacy and leaves no implant behind, while surgical reconstruction offers definitive cures for localized stenosis in fit patients. Techniques such as laser, cryotherapy, and argon plasma coagulation recanalize blocked airways quickly, and Montgomery T-tubes provide another removable option in post-tracheotomy stenosis.

Device-Related Complications

Migration, granulation, and fracture remain leading concerns, with metallic devices often requiring complex extraction that carries bleeding and perforation risks. Up to 75% granulation incidence imposes repeated bronchoscopies, and infection risk escalates in immunocompromised patients. Long-term Mayo Clinic data showed a 22-month average before complications necessitated metallic-stent removal.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Self-Expandable Dominance Drives Innovation

Self-expandable devices accounted for 58.96% of 2025 revenue, confirming their versatility in treating both benign and malignant obstructions. These stents expand gently after deployment and maintain steady radial force, helping physicians manage variable airway diameters. Balloon-expandable units are designed for scenarios that require precise sizing, such as pediatric tracheal narrowing. Non-expandable and 3D-printed custom designs are projected to achieve an 8.78% CAGR through 2031. The shift toward personalized implants reflects a growing awareness that geometric differences necessitate tailored solutions. AnatomikModeling and Toulouse University Hospital executed one of the earliest custom placements in 2016 and have since demonstrated improved migration profiles in validation studies. Michigan Medicine’s 2025 infant trial marks a new frontier in resorbable, bespoke devices.

Self-expandable devices are reliable in collapse-prone segments, yet physicians increasingly prescribe custom-printed stents for airways distorted by tumors or postsurgical changes. This trend aligns with hospital investment in point-of-care 3D-printing labs that compress turnaround times and lower logistic costs. As these centers mature, non-expandable personalized units will claim a larger slice of the airway stent/lung stent market, even as self-expandable lines remain workhorse solutions for general obstruction.

By Material: Metal Leadership Faces Polymer Challenge

Metal frameworks remain the default in rapidly progressing tumors due to their high radial strength and radiopaque profiles, which facilitate imaging follow-up. They captured 50.83% of 2025 sales. Yet, biodegradable polymers are the fastest risers, with a 9.07% CAGR through 2031, as clinicians prize temporary support without the burden of removal surgery. Silicone options remain popular in benign diseases because they are less prone to infection and can be easily extracted. Composite designs that combine metal skeletons with polymer linings aim to achieve the best of both worlds, incorporating drug-eluting layers to mitigate granulation.

In adult trials, polydioxanone devices demonstrated 89.7% clinical effectiveness and subsequently resorbed, thereby freeing the airway from foreign material. Iron-scaffold data revealed 95.4% absorption within three years with no loss of mechanical stability. Surface laser texturing promoted endothelial growth while reducing smooth-muscle proliferation by approximately 75%, which can lower the risk of restenosis. As price gaps narrow, polymer adoption will accelerate, shrinking metal’s share of the airway stent/lung stent market.

By Type: Tracheobronchial Stents Lead Specialized Applications

Tracheobronchial models delivered 65.52% of 2025 revenue due to their broad utility in both central airways. Y-shaped carinal stents, though with a smaller base, are expanding briskly at an 8.66% CAGR, driven by transplant-associated bifurcation complications. Laryngeal devices cover niche indications where upper-airway patency is threatened after trauma or oncologic resections.

The clinical benefit of Y-stents in lung transplant recipients is notable; secondary carina placements reduce repeat procedures by two-thirds while tripling the time between interventions. Angulated designs targeting post-tuberculosis bronchostenosis highlight how geometry-specific engineering enhances dwell time and reduces migration. As surgical volumes rise and transplant survival extends, the need for complex bifurcation devices will grow in the airway stent/lung stent market.

By Indication: Malignant Obstruction Drives Core Demand

Lung-cancer-related obstruction made up 53.73% of 2025 sales, and the palliative benefit of restoring airflow remains central to demand. Post-transplant complications, although smaller, constitute the fastest-growing indication at 9.32% CAGR, fueled by expanding transplant programs and lengthening graft survival. Benign tracheal stenosis maintains a stable user base that is increasingly opting for resorbable stents. Tracheoesophageal fistulas need covered models that isolate the airway from the digestive tract.

Standardized grading from the International Society for Heart and Lung Transplantation aids uniform decision-making and builds a stable case volume for interventional pulmonologists. In esophageal carcinoma with airway involvement, median survival stretches to 97 days post-stenting, underscoring life-quality gains even in late-stage disease.

By End User: Hospitals Dominate While Specialty Clinics Surge

Hospitals retained a 66.22% share in 2025, supported by intensive care units and on-call thoracic surgery teams for emergencies. However, specialty pulmonology clinics are expected to experience a 10.06% CAGR to 2031, driven by the adoption of outpatient bronchoscopy and robotic platforms that reduce procedure times. Ambulatory surgical centers win business with transparent pricing and same-day discharge policies.

A scoping review on intensive-care pulmonology confirms stent placement as a critical option for mechanically ventilated patients with central obstruction. Jet-ventilation success rates of 84% show that specialized centers can achieve high efficiency. As payers push care into lower-cost settings, clinics that can combine advanced imaging, custom printing, and robotic guidance will capture an incremental share of the airway stent/lung stent market volume.

Geography Analysis

North America generated 38.45% of revenue in 2025, underpinned by advanced reimbursement policies and rapid adoption of precision placement technologies. The FDA’s 2024 De Novo clearance for Peytant’s stent system demonstrates a supportive regulatory climate. The forthcoming Quality System Regulation alignment with ISO standards by 2026 will streamline manufacturing compliance and help innovative devices reach hospitals more quickly. Robotic bronchoscopy diagnostic yields of up to 94% solidify the region’s leadership in technology-driven care. While Medicare covers core interventional pulmonology codes, payment gaps persist for customized implants, tempering near-term adoption of 3D-printed solutions.

The Asia-Pacific region is the growth engine, with a 9.2% CAGR projected to 2031. COPD prevalence, 37.8 million cases in India alone, aligns with high urban air-pollution exposure and smoking rates. China’s hospital build-out and a rising middle class are expanding the treated population, despite a 22% decline in medtech investment in 2024 amid tighter capital markets. Japan’s so-called device-lag underscores approval delays, but recent harmonization initiatives aim to shorten the time to market. Together, these dynamics create a sizable addressable base for the airway stent/lung stent market.

Europe offers steady expansion supported by universal healthcare and a strong evidence culture. AnatomikModeling’s collaboration with Toulouse University Hospital showcases the continent’s prowess in custom 3D stents. Multi-center biodegradable trials report 89.7% effectiveness, keeping Europe at the forefront of resorbable research [bmcpulmmed.biomedcentral.com]. The Medical Device Regulation establishes uniform safety benchmarks that facilitate cross-border device adoption, although cost pressures necessitate demonstrable value before large-scale deployment.

Regulatory Landscape

Airway stents are regulated as moderate-to-high risk implantable devices, with requirements shaped by material (metal, silicone, hybrid, bioresorbable polymers) and any drug-eluting or coated functionality. In the United States, tracheal/airway stents commonly follow Class II controls under 21 CFR 878.3720 and are frequently cleared via the 510(k) pathway, while novel platforms can proceed through FDA pathways such as De Novo, as seen with Peytant Solutions covered stent system clearance in 2024.

In Europe, airway stents fall under the Medical Device Regulation (EU) 2017/745 with conformity assessment through Notified Bodies, and manufacturers must meet Annex I General Safety and Performance Requirements. Products that integrate a drug constituent face added combination-product coordination, including interaction with EMA structures that address device constituents for combination products. Across regions, biological safety and risk management expectations commonly reference ISO 10993-1 for biocompatibility evaluation, which raises the documentation bar for newer materials and patient-specific designs where long-term contact and individualized geometry complicate test strategies.

Value Chain Analysis

The value chain starts with specialty raw materials, including nitinol and other alloys for self-expanding frames, medical-grade silicone, and emerging bioresorbable polymers. It then moves through precision conversion (laser cutting, electropolishing, braiding, and molding/extrusion), followed by coating for covered or drug-eluting variants, and ends with sterilization and packaging. Clinical distribution typically runs through hospitals, interventional pulmonology centers, and specialty clinics.

Quality and regulatory documentation are built into the manufacturing workflow, with design controls, biocompatibility files, and performance testing acting as gating items for market access, particularly for covered and drug-device combination designs. Supply continuity and customization logistics create friction points as well. Lead times and single-source dependencies for specific implant-grade silicone formulations and validated biocompatibility packages can constrain output, while patient-specific and 3D-printed workflows add steps such as imaging-to-CAD conversion, physician sign-off, and lot-specific verification. On the commercial side, distribution often relies on direct sales and specialized procedural channels, and procurement is shifting toward system-level contracting and bundled purchasing that favors suppliers able to provide broad stent portfolios (metal, silicone, hybrid) alongside procedural support for bronchoscopic placement.

Market Opportunities and Future Outlook

White space appears most clearly tied to reducing complications and improving removability, especially in benign stenosis management where restenosis and granulation drive repeat bronchoscopies, and in post-lung-transplant airway complications that can require complex geometries such as Y-shaped carinal designs. Active innovation is also visible in clinical pipeline updates, including Michigan Medicine opening a 35-patient infant trial in March 2025 for 3D-printed bioresorbable airway devices, which supports momentum around patient-specific, dissolving scaffolds that aim to avoid removal procedures.

Next-generation platforms create additional room for differentiation across both product and placement workflows. FDA clearance activity supports continued iteration through established pathways, including the 2024 De Novo clearance for Peytant Solutions and a June 2026 510(k) clearance for VisionAir Solutions (VisionAir Enhanced Stock Stent, under 21 CFR 878.3720), pointing to continued regulatory throughput for new and improved airway stent systems. At the same time, 2026 R&D coverage on drug-eluting and bioresorbable constructs, including coated and multifunctional coverings aimed at anti-inflammatory or anti-fibrotic effects, highlights an opportunity for manufacturers that pair airway stents with controlled-release coatings and validated biocompatibility, while aligning offerings to outpatient bronchoscopy growth in specialty pulmonology clinics.